乳腺癌患者新发心血管疾病预测模型的建立与验证：基于内蒙古区域医疗数据

doi:10.19723/j.issn.1671-167X.2023.03.013

Abstract

Abstract:

Objective: To develop and validate a three-year risk prediction model for new-onset cardiovascular diseases (CVD) among female patients with breast cancer. Methods: Based on the data from Inner Mongolia Regional Healthcare Information Platform, female breast cancer patients over 18 years old who had received anti-tumor treatments were included. The candidate predictors were selected by Lasso regression after being included according to the results of the multivariate Fine & Gray model. Cox proportional hazard model, Logistic regression model, Fine & Gray model, random forest model, and XGBoost model were trained on the training set, and the model performance was evaluated on the testing set. The discrimination was evaluated by the area under the curve (AUC) of the receiver operator characteristic curve (ROC), and the calibration was evaluated by the calibration curve. Results: A total of 19 325 breast cancer patients were identified, with an average age of (52.76±10.44) years. The median follow-up was 1.18 [interquartile range (IQR): 2.71] years. In the study, 7 856 patients (40.65%) developed CVD within 3 years after the diagnosis of breast cancer. The final selected variables included age at diagnosis of breast cancer, gross domestic product (GDP) of residence, tumor stage, history of hypertension, ischemic heart disease, and cerebrovascular disease, type of surgery, type of chemotherapy and radiotherapy. In terms of model discrimination, when not considering survival time, the AUC of the XGBoost model was significantly higher than that of the random forest model [0.660 (95%CI: 0.644-0.675) vs. 0.608 (95%CI: 0.591-0.624), P < 0.001] and Logistic regression model [0.609 (95%CI: 0.593-0.625), P < 0.001]. The Logistic regression model and the XGBoost model showed better calibration. When considering survival time, Cox proportional hazard model and Fine & Gray model showed no significant difference for AUC [0.600 (95%CI: 0.584-0.616) vs. 0.615 (95%CI: 0.599-0.631), P=0.188], but Fine & Gray model showed better calibration. Conclusion: It is feasible to develop a risk prediction model for new-onset CVD of breast cancer based on regional medical data in China. When not considering survival time, the XGBoost model and the Logistic regression model both showed better performance; Fine & Gray model showed better performance in consideration of survival time.

Key words: Breast neoplasms, Cardiovascular disease, Risk prediction model, Risk assessment, Computerized medical records systems

CLC Number:

R737.9

Yun-jing ZHANG,Li-ying QIAO,Meng QI,Ying YAN,Wei-wei KANG,Guo-zhen LIU,Ming-yuan WANG,Yun-feng XI,Sheng-feng WANG. Development and validation of risk prediction model for new-onset cardiovascular diseases among breast cancer patients: Based on regional medical data of Inner Mongolia[J].Journal of Peking University (Health Sciences), 2023, 55(3): 471-479.

Figures/Tables 6

Table 1

The information of variables included in the prediction model for CVD among breast cancer patients in the Inner Mongolia Autonomous Region from 2012 to 2021"

Variables	Measurement	Variable assignments
Age on set	Age at diagnosis of breast cancer according to birthday and date of diagnosis	Years
Type of medical insurance	Type of medical insurance	0=employee, 1=residence
Ethnicity	Ethnicity according to medical insurance data	0=Han, 1=Mongolian, 2=others
GDP of residence	GDP of district where patients lived according to Inner Mongolia Bureau of Statistics	100 million yuan
Tumor stage	According to clinical TNM stage and treatment patterns. Stage=0, 1, 2, 3 was defined as “early” while stage=4 was defined as “advanced”	0=early, 1=unknown, 2=advanced
Type of surgery	According to records of treatments from medical insurance data	0=none, 1=breast-conserving surgery, 2=mastectomy
Type of chemotherapy	According to records of treatments from medical insurance data	0=none, 1=anthracyclines, 2=non-anthracyclines
Endocrine therapy	According to records of treatments from medical insurance data	0=no, 1=yes
Type of targeted therapy	According to records of treatments from medical insurance data	0=none, 1=trastuzumab, 2=non-trastuzumab
Radiotherapy	According to records of treatments from medical insurance data	0=no, 1=yes
History of diabetes	According to records of medical insurance before breast cancer diagnosis	0=no, 1=yes
History of renal diseases	According to records of medical insurance before breast cancer diagnosis	0=no, 1=yes
History of hypertension	According to records of medical insurance before breast cancer diagnosis	0=no, 1=yes
History of ischemic heart diseases	According to records of medical insurance before breast cancer diagnosis	0=no, 1=yes
History of cerebrovascular diseases	According to records of medical insurance before breast cancer diagnosis	0=no, 1=yes
History of dyslipidemia	According to records of medical insurance before breast cancer diagnosis	0=no, 1=yes
History of hypothyroidism	According to records of medical insurance before breast cancer diagnosis	0=no, 1=yes
History of hyperthyroidism	According to records of medical insurance before breast cancer diagnosis	0=no, 1=yes
Charlson comorbidity index	According to records of medical insurance	Points
Hospitalization before diagnosis within 1 year	According to records of medical insurance before breast cancer diagnosis within 1 year	0=no, 1=yes
Length of stay before diagnosis within 1 year	According to the duration of hospitalization records from medical insurance before breast cancer diagnosis within 1 year	Days

Table 1

Table 2

Demographic characteristics of breast cancer patients receiving anti-tumor treatment in the Inner Mongolia Autonomous Region from 2012 to 2021"

Items	CVD (n=7 856)	No CVD (n=11 469)	P value
Age onset/years, ${\bar x}$±s	53.48±10.38	52.28±10.45	< 0.001
Type of medical insurance, n (%)			< 0.001
Employee	4 291 (54.62)	6 829 (59.54)
Resident	3 565 (45.38)	4 640 (40.46)
Ethnicity, n (%)			0.002
Han	6 727 (85.63)	9 620 (83.88)
Mongolian	865 (11.01)	1 372 (11.96)
Others	263 (3.35)	473 (4.12)
GDP of residence, median (IQR)	156.21 (180.36)	174.46 (312.93)	< 0.001
Charlson comorbidity index, ${\bar x}$±s	1.89±3.32	1.84±3.24	0.254
Tumor stage, n (%)			< 0.001
Early	3 619 (46.07)	4 807 (41.91)
Advanced	3 114 (39.64)	4 680 (40.81)
Unknown	1 123 (14.29)	1 982 (17.28)
Previous disease history, n (%)
Dyslipidemia	943 (12.00)	2 202 (19.20)	< 0.001
Diabetes	943 (12.00)	2 202 (19.20)	< 0.001
Renal diseases	81 (1.03)	181 (1.58)	0.002
Hypertension	1 325 (16.87)	3 535 (30.82)	< 0.001
Ischemic heart diseases	435 (5.54)	1 313 (11.45)	< 0.001
Cerebrovascular diseases	547 (6.96)	1 372 (11.96)	< 0.001
Hyperthyroidism	10 (0.13)	26 (0.23)	0.160
Hypothyroidism	9 (0.11)	24 (0.21)	0.165
Hospitalization before diagnosis within 1 year, n (%)	1 743 (22.19)	3 309 (28.85)	< 0.001
Length of stay before diagnosis within 1 year, ${\bar x}$±s	2.88±9.15	3.67±8.99	< 0.001
Type of surgery, n (%)			< 0.001
Mastectomy	3 262 (41.52)	3 910 (34.09)
Breast-conserving	247 (3.14)	495 (4.32)
None	4 347 (55.33)	7 064 (61.59)
Type of chemotherapy, n (%)			< 0.001
Anthracyclines	3 399 (43.27)	4 299 (37.48)
Non-anthracyclines	2 394 (30.47)	3 593 (31.33)
None	2 063 (26.26)	3 577 (31.19)
Endocrine therapy, n (%)	4 669 (59.43)	7 114 (62.03)	< 0.001
Type of targeted therapy, n (%)			0.018
Trastuzumab	1 023 (13.02)	1 649 (14.38)
Non-trastuzumab	67 (0.85)	111 (0.97)
None	6 766 (86.13)	9 709 (84.65)
Radiotherapy, n (%)	587 (7.47)	533 (4.65)	< 0.001

Table 2

Table 3

Results of multivariate competing risk models for breast cancer patients receiving anti-tumor treatment in the Inner Mongolia Autonomous Region from 2012 to 2021"

Factor	β	SE	Wald χ²	HR (95%CI)	P value
Age onset/years	0.02	0.00	14.17	1.02 (1.01-1.02)	< 0.001
Type of medical insurance
Employee				1.00
Resident	-0.03	0.03	-1.05	0.97 (0.92-1.03)	0.290
Ethnicity
Han				1.00
Mongolian	0.00	0.04	0.12	1.00 (0.94-1.08)	0.910
Others	-0.13	0.06	-2.02	0.88 (0.78-1.00)	0.043
GDP of residence	0.00	0.00	-8.36	1.00 (1.00-1.00)	< 0.001
Charlson comorbidity index	0.00	0.00	-0.40	1.00 (0.99-1.01)	0.690
Tumor stage
Early				1.00
Advanced	-0.14	0.04	-3.44	0.87 (0.80-0.94)	0.001
Unknown	-0.06	0.03	-2.15	0.94 (0.88-0.99)	0.031
Type of surgery
None				1.00
Breast-conserving	0.06	0.07	0.83	1.06 (0.92-1.22)	0.410
Mastectomy	0.27	0.03	8.75	1.31 (1.23-1.39)	< 0.001
Type of chemotherapy
None				1.00
Anthracyclines	0.19	0.03	6.22	1.21 (1.14-1.29)	< 0.001
Non-anthracyclines	0.11	0.03	3.48	1.11 (1.05-1.18)	< 0.001
Endocrine therapy
No				1.00
Yes	-0.10	0.02	-4.07	0.90 (0.86-0.95)	< 0.001
Type of targeted therapy
None				1.00
Trastuzumab	-0.01	0.03	-0.26	0.99 (0.93-1.06)	0.790
Non-trastuzumab	-0.04	0.12	-0.33	0.96 (0.76-1.21)	0.740
Radiotherapy
No				1.00
Yes	0.26	0.05	5.35	1.30 (1.18-1.42)	< 0.001
History of hypertension
No				1.00
Yes	-0.44	0.04	-11.52	0.64 (0.60-0.69)	< 0.001
History of dyslipidemia
No				1.00
Yes	-0.02	0.04	-0.53	0.98 (0.90-1.06)	0.590
History of diabetes
No				1.00
Yes	0.03	0.04	0.83	1.03 (0.96-1.12)	0.410
History of ischemic heart diseases
No				1.00
Yes	-0.35	0.06	-6.31	0.71 (0.63-0.79)	< 0.001
History of cerebrovascular diseases
No				1.00
Yes	-0.05	0.05	-1.07	0.95 (0.86-1.05)	0.280
History of renal diseases
No				1.00
Yes	0.08	0.12	0.72	1.09 (0.87-1.36)	0.470
History of hyperthyroidism
No				1.00
Yes	-0.07	0.32	-0.22	0.93 (0.50-1.75)	0.830
History of hypothyroidism
No				1.00
Yes	0.01	0.32	0.02	1.01 (0.53-1.90)	0.980
Hospitalization before diagnosis within 1 year
No				1.00
Yes	-0.07	0.04	-1.75	0.93 (0.86-1.01)	0.081
Length of stay before diagnosis within 1 year	0.00	0.00	-1.20	1.00 (0.99-1.00)	0.230

Table 3

Figure 1

Figure 2

Figure 3

References 47

1	International Agency for Research on Cancer. World cancer day: Breast cancer overtakes lung cancer as leading cause of cancer worldwide. IARC showcases key research projects to address breast cancer [EB/OL]. (2021-02-04) [2023-02-20]. https://www.iarc.who.int/news-events/world-cancer-day-2021/.
2	Connor AE , Schmaltz CL , Jackson-Thompson J , et al. Comorbidities and the risk of cardiovascular disease mortality among racially diverse patients with breast cancer[J]. Cancer, 2021, 127 (15): 2614- 2622. doi: 10.1002/cncr.33530
3	Abdel-Qadir H , Austin PC , Lee DS , et al. A population-based study of cardiovascular mortality following early-stage breast cancer[J]. JAMA Cardiol, 2017, 2 (1): 88- 93. doi: 10.1001/jamacardio.2016.3841
4	Sturgeon KM , Deng L , Bluethmann SM , et al. A population-based study of cardiovascular disease mortality risk in US cancer patients[J]. Eur Heart J, 2019, 40 (48): 3889- 3897. doi: 10.1093/eurheartj/ehz766
5	Padegimas A , Clasen S , Ky B . Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity[J]. Trends Cardiovasc Med, 2020, 30 (1): 22- 28. doi: 10.1016/j.tcm.2019.01.006
6	Mehta LS , Watson KE , Barac A , et al. Cardiovascular disease and breast cancer: Where these entities intersect: A scientific statement from the American Heart Association[J]. Circulation, 2018, 137 (8): e30- e66.
7	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021版)[J]. 中国癌症杂志, 2021, 31 (10): 954- 1040.
8	Li J , Qiang WM , Wang Y , et al. Development and validation of a risk assessment nomogram for venous thromboembolism associated with hospitalized postoperative Chinese breast cancer patients[J]. J Adv Nurs, 2021, 77 (1): 473- 483. doi: 10.1111/jan.14571
9	Ezaz G , Long JB , Gross CP , et al. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer[J]. J Am Heart Assoc, 2014, 3 (1): e000472. doi: 10.1161/JAHA.113.000472
10	Fogarassy G , Vathy-Fogarassy Á , Kenessey I , et al. Risk prediction model for long-term heart failure incidence after epirubicin chemotherapy for breast cancer: A real-world data-based, nationwide classification analysis[J]. Int J Cardiol, 2019, 285, 47- 52. doi: 10.1016/j.ijcard.2019.03.013
11	Romond EH , Jeong JH , Rastogi P , et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer[J]. J Clin Oncol, 2012, 30 (31): 3792- 3799. doi: 10.1200/JCO.2011.40.0010
12	Abdel-Qadir H , Thavendiranathan P , Austin PC , et al. Development and validation of a multivariable prediction model for major adverse cardiovascular events after early stage breast cancer: A population-based cohort study[J]. Eur Heart J, 2019, 40 (48): 3913- 3920. doi: 10.1093/eurheartj/ehz460
13	Dranitsaris G , Rayson D , Vincent M , et al. The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines[J]. Breast Cancer Res Treat, 2008, 107 (3): 443- 450. doi: 10.1007/s10549-007-9803-5
14	Kim DY , Park MS , Youn JC , et al. Development and validation of a risk score model for predicting the cardiovascular outcomes after breast cancer therapy: The CHEMO-RADIAT score[J]. J Am Heart Assoc, 2021, 10 (16): e021931. doi: 10.1161/JAHA.121.021931
15	Rushton M , Johnson C , Dent S . Trastuzumab-induced cardiotoxi-city: Testing a clinical risk score in a real-world cardio-oncology population[J]. Curr Oncol, 2017, 24 (3): 176- 180.
16	Chang WT , Liu CF , Feng YH , et al. An artificial intelligence approach for predicting cardiotoxicity in breast cancer patients receiving anthracycline[J]. Arch Toxicol, 2022, 96 (10): 2731- 2737. doi: 10.1007/s00204-022-03341-y
17	Zamorano JL , Lancellotti P , Rodriguez Munoz D , et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)[J]. Eur J Heart Fail, 2017, 19 (1): 9- 42. doi: 10.1002/ejhf.654
18	World Health Organization. Cardiovascular diseases (CVDs) [EB/OL]. (2021-6-11) [2023-12-14]. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
19	胡盛寿, 高润霖, 刘力生, 等. 《中国心血管病报告2018》概要[J]. 中国循环杂志, 2019, 34 (3): 209- 220. doi: 10.3969/j.issn.1000-3614.2019.03.001
20	中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2019概要[J]. 中国循环杂志, 2020, 35 (9): 833- 854.
21	Grundy SM , Stone NJ , Bailey AL , et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines[J]. Circulation, 2019, 139 (25): e1082- e1143.
22	Chien HC , Kao Yang YH , Bai JP . Trastuzumab-related cardio-toxic effects in Taiwanese women: A nationwide cohort study[J]. JAMA Oncol, 2016, 2 (10): 1317- 1325. doi: 10.1001/jamaoncol.2016.1269
23	内蒙古自治区统计局. 国民经济核算-地区生产总值-各盟市年度数据[EB/OL]. (2021-03-01) [2023-02-20]. http://tj.nmg.gov.cn/datashow/easyquery/easyquery.htm?cn=B0103.
24	Charlson ME , Pompei P , Ales KL , et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation[J]. J Chronic Dis, 1987, 40 (5): 373- 383. doi: 10.1016/0021-9681(87)90171-8
25	王俊峰, 章仲恒, 周支瑞, 等. 临床预测模型: 模型的验证[J]. 中国循证心血管医学杂志, 2019, 11 (2): 141- 144. doi: 10.3969/j.issn.1674-4055.2019.02.04
26	中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2021概要[J]. 中国循环杂志, 2022, 37 (6): 553- 578. doi: 10.3969/j.issn.1000-3614.2022.06.001
27	Sutton AL, Felix AS, Wahl S, et al. Racial disparities in treatment-related cardiovascular toxicities amongst women with breast cancer: A scoping review [J/OL]. J Cancer Surviv, 2022, [2022-04-14]. https://doi.org/10.1007/s11764-022-01210-2.
28	戴芮. 心脑血管疾病"协防共管"健康管理模式评价指标体系研究[D]. 江苏: 南京医科大学, 2021.
29	林晓斐. 国务院办公厅印发《中国防治慢性病中长期规划(2017—2025年)》[J]. 中医药管理杂志, 2017, 25 (4): 14.
30	Battisti NML , Andres MS , Lee KA , et al. Incidence of cardio-toxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer[J]. Breast Cancer Res Treat, 2021, 188 (1): 149- 163. doi: 10.1007/s10549-021-06192-w
31	D'Agostino RB Sr , Vasan RS , Pencina MJ , et al. General car-diovascular risk profile for use in primary care: the Framingham Heart Study[J]. Circulation, 2008, 117 (6): 743- 753. doi: 10.1161/CIRCULATIONAHA.107.699579
32	Guha A , Fradley MG , Dent SF , et al. Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: A SEER-Medicare analysis[J]. Eur Heart J, 2022, 43 (4): 300- 312. doi: 10.1093/eurheartj/ehab745
33	Henry ML , Niu J , Zhang N , et al. Cardiotoxicity and cardiac monitoring among chemotherapy-treated breast cancer patients[J]. JACC Cardiovasc Imaging, 2018, 11 (8): 1084- 1093. doi: 10.1016/j.jcmg.2018.06.005
34	Boekel NB , Jacobse JN , Schaapveld M , et al. Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer[J]. Br J Cancer, 2018, 119 (4): 408- 418. doi: 10.1038/s41416-018-0159-x
35	Giordano G , Spagnuolo A , Olivieri N , et al. Cancer drug related cardiotoxicity during breast cancer treatment[J]. Expert Opin Drug Saf, 2016, 15 (8): 1063- 1074. doi: 10.1080/14740338.2016.1182493
36	Zhang S , Liu XB , Bawa-Khalfe T , et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity[J]. Nat Med, 2012, 18 (11): 1639- 1642. doi: 10.1038/nm.2919
37	Higuchi S , Kabeya Y , Matsushita K , et al. Incidence and complications of perioperative atrial fibrillation after non-cardiac surgery for malignancy[J]. PLoS One, 2019, 14 (5): e0216239. doi: 10.1371/journal.pone.0216239
38	内蒙古自治区医疗保障局. 关于执行国家基本医疗保险、工伤保险和生育保险药品目录(2019年版)的通知[EB/OL]. (2019-12-06) [2023-02-25]. https://ylbzj.nmg.gov.cn/zwgk/zfxxgk/fdzdgknr/bmwj/202103/t20210326_1313389.html.
39	Nusinovici S , Tham YC , Chak Yan MY , et al. Logistic regression was as good as machine learning for predicting major chronic diseases[J]. J Clin Epidemiol, 2020, 122, 56- 69. doi: 10.1016/j.jclinepi.2020.03.002
40	James G , Witten D , Hastie T , et al. An introduction to statistical learning with application in R[M]. New York: Springer, 2013.
41	Hastie T , Tibshirani R , Friedman JH , et al. The elements of statistical learning: Data mining, inference and prediction[M]. New York: Springer, 2009.
42	International Agency for Research on Cancer. SURVCAN [EB/OL]. (2019-01-01) [2023-02-20]. https://gco.iarc.fr/survi-val/survcan/dataviz/table?mode=population&population_group=Asia&cancers=180&survival=5.
43	Nolan EK , Chen HY . A comparison of the Cox model to the Fine-Gray model for survival analyses of re-fracture rates[J]. Arch Osteoporos, 2020, 15 (1): 86. doi: 10.1007/s11657-020-00748-x
44	Putter H , Fiocco M , Geskus RB . Tutorial in biostatistics: Competing risks and multi-state models[J]. Stat Med, 2007, 26 (11): 2389- 2430. doi: 10.1002/sim.2712
45	惠春霞, 陈文婕, 钱永刚, 等. 内蒙古自治区居民超重/肥胖多水平分析[J]. 慢性病学杂志, 2020, 21 (3): 319- 322.
46	王瑞琪, 杜茂林, 梁丹艳, 等. 内蒙古地区流动人口糖尿病影响因素的研究[J]. 现代预防医学, 2018, 45 (1): 155- 159.
47	Galovic M , Döhler N , Erdélyi-Canavese B , et al. Prediction of late seizures after ischaemic stroke with a novel prognostic model (the SeLECT score): A multivariable prediction model development and validation study[J]. Lancet Neurol, 2018, 17 (2): 143- 152. doi: 10.1016/S1474-4422(17)30404-0

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Comments

Recommended 10

[1]	. [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 225 -328 .
[2]	. [J]. Journal of Peking University(Health Sciences), 2007, 39(5): 498 -502 .
[3]	. [J]. Journal of Peking University(Health Sciences), 2000, 32(4): 300 .
[4]	. [J]. Journal of Peking University(Health Sciences), 2001, 33(6): 559 -561 .
[5]	. [J]. Journal of Peking University(Health Sciences), 2001, 33(6): 565 .
[6]	. [J]. Journal of Peking University(Health Sciences), 2008, 40(1): 39 -42 .
[7]	. [J]. Journal of Peking University(Health Sciences), 2008, 40(6): 600 -602 .
[8]	. [J]. Journal of Peking University(Health Sciences), 2009, 41(5): 537 -540 .
[9]	. [J]. Journal of Peking University(Health Sciences), 2009, 41(1): 90 -94 .
[10]	. [J]. Journal of Peking University(Health Sciences), 2003, 35(4): 382 -385 .

[1]	Tianjing ZHOU,Qiuping LIU,Minglu ZHANG,Xiaofei LIU,Jiali KANG,Peng SHEN,Hongbo LIN,Xun TANG,Pei GAO. Comparison of initiation of antihypertensive therapy strategies for primary prevention of cardiovascular diseases in Chinese population: A decision-analytic Markov modelling study [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 441-447.
[2]	Chu-yun CHEN,Peng-fei SUN,Jing ZHAO,Jia JIA,Fang-fang FAN,Chun-yan WANG,Jian-ping LI,Yi-meng JIANG,Yong HUO,Yan ZHANG. Related factors of endogenous erythropoietin and its association with 10-year risks of cardiovascular disease in a community-based Chinese study [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1068-1073.
[3]	Jian-xun MA,You-chen XIA,Bi LI,Hong-mei ZHAO,Yu-tao LEI,Xi BU. Choice of immediate breast reconstructive methods after modified radical mastectomy [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 612-618.
[4]	Zi-wei ZHANG,Yu-meng HUA,Ai-ping LIU. Joint association of depression symptoms and 10-year risk of ischemic cardiovascular disease with the cardiovascular disease in middle-aged and elderly people in China [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 465-470.
[5]	Ming-lu ZHANG,Qiu-ping LIU,Chao GONG,Jia-min WANG,Tian-jing ZHOU,Xiao-fei LIU,Peng SHEN,Hong-bo LIN,Xun TANG,Pei GAO. Comparison of aspirin treatment strategies for primary prevention of cardiovascular diseases: A decision-analytic Markov modelling study [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 480-487.
[6]	Zhe LIANG,Fang-fang FAN,Yan ZHANG,Xian-hui QIN,Jian-ping LI,Yong HUO. Rate and characteristics of H-type hypertension in Chinese hypertensive population and comparison with American population [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 1028-1037.
[7]	Yue WANG,Shuang ZHANG,Hong ZHANG,Li LIANG,Ling XU,Yuan-jia CHENG,Xue-ning DUAN,Yin-hua LIU,Ting LI. Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 853-862.
[8]	Chao GONG,Qiu-ping LIU,Jia-min WANG,Xiao-fei LIU,Ming-lu ZHANG,Han YANG,Peng SHEN,Hong-bo LIN,Xun TANG,Pei GAO. Effectiveness of statin treatment strategies for primary prevention of cardiovascular diseases in a community-based Chinese population: A decision-analytic Markov model [J]. Journal of Peking University (Health Sciences), 2022, 54(3): 443-449.
[9]	Jia-min WANG,Qiu-ping LIU,Ming-lu ZHANG,Chao GONG,Shu-dan LIU,Wei-ye CHEN,Peng SHEN,Hong-bo LIN,Pei GAO,Xun TANG. Effectiveness of different screening strategies for type 2 diabete on preventing cardiovascular diseases in a community-based Chinese population using a decision-analytic Markov model [J]. Journal of Peking University (Health Sciences), 2022, 54(3): 450-457.
[10]	GUO Zi-ning, LIANG Zhi-sheng, ZHOU Yi, ZHANG Na, HUANG Jie. Genetic study of cardiovascular disease subtypes defined by International Classification of Diseases [J]. Journal of Peking University (Health Sciences), 2021, 53(3): 453-459.
[11]	LIU Qiu-ping,CHEN Xi-jin,WANG Jia-min,LIU Xiao-fei,SI Ya-qin,LIANG Jing-yuan,SHEN Peng,LIN Hong-bo,TANG Xun,GAO Pei. Effectiveness of different screening strategies for cardiovascular diseases prevention in a community-based Chinese population: A decision-analytic Markov model [J]. Journal of Peking University (Health Sciences), 2021, 53(3): 460-466.
[12]	Jia-li CHEN,Yue-bo JIN,Yi-fan WANG,Xiao-ying ZHANG,Jing LI,Hai-hong YAO,Jing HE,Chun LI. Clinical characteristics and risk factors of cardiovascular disease in patients with elderly-onset rheumatoid arthritis: A large cross-sectional clinical study [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1040-1047.
[13]	Huan LIU,Ying-dong HE,Jin-bo LIU,Wei HUANG,Na ZHAO,Hong-wei ZHAO,Xiao-hua ZHOU,Hong-yu WANG. Predictive value of vascular health indicators on newly cardiovascular events: Preliminary validation of Beijing vascular health stratification system [J]. Journal of Peking University (Health Sciences), 2020, 52(3): 514-520.
[14]	Guo-hong SONG,Hui-ping LI,Li-jun DI,Ying YAN,Han-fang JIANG,Ling XU,Dong-gui WAN,Ying LI,Mo-pei WANG,Yu XIAO,Ru-yan ZHANG,Ran RAN,Huan WANG. Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice [J]. Journal of Peking University (Health Sciences), 2020, 52(2): 254-260.
[15]	Chuan REN,Xiao-yue WU,Wei ZHAO,Li-yuan TAO,Ping LIU,Wei GAO. Protective effect of cardiopulmonary fitness on patients with high risk of atherosclerotic cardiovascular disease [J]. Journal of Peking University(Health Sciences), 2020, 52(1): 152-157.

Development and validation of risk prediction model for new-onset cardiovascular diseases among breast cancer patients: Based on regional medical data of Inner Mongolia

RICH HTML

PDF (PC)

Abstract

Cite this article

share this article

Figures/Tables 6

References 47

Related Articles 15

Metrics

Comments

Recommended 10